Allometric scaling of xenobiotic clearance uncertainty versus universality

AAPS PharmSci

Volumn 3, Issue 4, 2001, Pages

  Hu, Teh Min ^a   Hayton, William L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Allometric scaling; Body weight; Clearance; Exponent; Metabolic rate; Metabolism; Monte Carlo; Pharmacokinetics; Power law; Simulation

Indexed keywords

XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; MONTE CARLO METHOD; NONHUMAN; PUBLISHING; SPECIES COMPARISON; STATISTICAL ANALYSIS; URINARY EXCRETION; ANIMAL; CAT; CATTLE; CHICKEN; COMPARATIVE STUDY; COMPUTER SIMULATION; DOG; GOAT; GUINEA PIG; HUMAN; MOUSE; PAN TROGLODYTES; PAPIO; PIGEONS AND DOVES; PROBABILITY; RABBIT; RAT; SHEEP; STATISTICS;

ANIMALS; CATS; CATTLE; CHICKENS; COLUMBIDAE; COMPUTER SIMULATION; DOGS; GOATS; GUINEA PIGS; HUMANS; MICE; MONTE CARLO METHOD; PAN TROGLODYTES; PAPIO; PROBABILITY; RABBITS; RATS; SHEEP; XENOBIOTICS;

EID: 85046914133     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps030429     Document Type: Article

References (103)

1. Schmidt-Nielsen K. Scaling: Why Is Animal Size So Important? Princeton, NJ: Cambridge University Press, 1983.
2. Calder WA III. Size, Function and Life History. Cambridge, MA: Harvard University Press, 1984.
3. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122-126.
4. West GB, Brown JH, Enquist BJ. The fourth dimension of life: Fractal geometry and allometric scaling of organisms. Science. 1999;284:1677-1679.
5. Kleiber M. Body size and metabolism. Hilgardia. 1932;6:315-353.
6. Heusner AA. Energy metabolism and body size. I. Is the 0.75 mass exponent of Kleiber's equation a statistical artifact? Respir Physiol. 1982;48:1-12.
7. Feldman HA, McMahon TA. The 3/4 mass exponent for energy metabolism is not a statistical artifact. Respir Physiol. 1983;52:149-163.
8. Banavar JR, Maritan A, Rinaldo A. Size and form in efficient transportation networks. Nature. 1999;399:130-132.
9. Dodds PS, Rothman DH, Weitz JS. Re-examination of the "3/4-law" of metabolism. J Theor Biol. 2001;209:9-27.
10. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokin Biopharm. 1982;10:201-227.
11. Sawada Y, Hanano M, Sugiyama Y, Iga T. Prediction of disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokin Biopharm. 1984;12:241-261.
12. Mordenti J. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci. 1986;75:1028-1040.
13. Mahmood I, Balian JD. Interspecies scaling: Prediction clearance of drugs in humans. Three different approaches. Xenobiotica. 1996;26:887-895.
14. Feng MR, Lou X, Brown RR, Hutchaleelaha A. Allometric pharmacokinetic scaling: Towards the prediction of human oral pharmacokinetics. Pharm Res. 2000;17:410-418.
15. Mahmood I. Interspecies scaling of renally secreted drugs. Life Sci. 1998;63:2365-2371.
16. McGovren JP, Williams MG, Stewart JC. Interspecies comparison of acivicin pharmacokinetics. Drug Metab Dispo. 1988;16:18-22.
17. Brazzell RK, Park YH, Wooldridge CB, et al. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metab Dispos. 1990;18:435-440.
18. Bjorkman S, Redke F. Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: Application to prediction of clearance in man. J Pharm Pharmacol. 2000;52:1065-1074.
19. Cherkofsky SC. 1-Aminocyclopropanecarboxylic acid: Mouse to man interspecies pharmacokinetic comparisons and allometric relationships. J Pharm Sci. 1995;84:1231-1235.
20. Robbie G, Chiou WL. Elucidation of human amphotericin b pharmacokinetics: Identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res. 1998;15:1630-1636.
21. Paxton JW, Kim SN, Whitfield LR. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res. 1990;50:2692-2697.
22. GreneLerouge NAM, Bazin-Redureau MI, Debray M, Schermann JM. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol. 1996;138:84-89.
23. Lave T, Dupin S, Schmidt C, Chou RC, Jaeck D, Coassolo PH. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci. 1997;86:584-590.
24. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol Appl Pharmacol. 1998;150:295-300.
25. Lashev LD, Pashov DA, Marinkov TN. Interspecies differences in the pharmacokinetics of kanamycin and apramycin. Vet Res Comm. 1992;16:293-300.
26. Patel BA, Boudinot FD, Schinazi RF, Gallo JM, Chu CK. Comparative pharmacokinetics and interspecies scaling of 3′-azido-3′-deoxy-thymidine (AZT) in several mammalian species. J Pharmacobio-Dyn. 1990;13:206-211.
27. Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, Kawahara Y. Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data. Antimicrob Ag Chemother. 1992;36:1810-1816.
28. Mehta SC, Lu DR. Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharm Drug Dispos. 1995;16:735-744.
29. Bonati M, Latini R, Tognoni G. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev. 1984-85;15:1355-1383.
30. Kaye B, Brearley CJ, Cussans NJ, Herron M, Humphrey MJ, Mollatt AR. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the produg candoxatril. Xenobiotica. 1997;27:1091-1102.
31. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991;8:1351-1359.
32. Sawada Y, Hanano M, Sugiyama Y, Iga T. Prediction of the disposition of b-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokinet Biopharm. 1984;12:241-261.
33. Matsushita H, Suzuki H, Sugiyama Y, et al. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J Pharmacobio-Dyn. 1990;13:602-611.
34. Mordenti J. Pharmacokinetic scale-up: Accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci. 1985;74:1097-1099.
35. Feng MR, Loo J, Wright J. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome p450 2D6 extensive metabolizers: Species comparison and allometric scaling. Drug Metab Dispos. 1998;26:982-988.
36. Hildebrand M. Inter-species extrapolation of pharmacokinetic data of three prostacyclin-mimetics. Prostaglandins. 1994;48:297-312.
37. Ericsson H, Tholander B, Bjorkman JA, Nordlander M, Regardh CG. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispo. 1999;27:558-564.
38. Sangalli L, Bortolotti A, Jiritano L, Bonati M. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metab Dispo. 1998;16:749-753.
39. Kim SH, Kim WB, Lee MG. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos. 1998;19:231-235.
40. Klotz U, Antonin K-H, Bieck PR. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther. 1976;199:67-73.
41. Kaul S, Daudekar KA, Schilling BE, Barbhaiya RH. Toxicokinetics of 2′,3′-deoxythymidine, stavudine (D4T). Drug Metab Dispos. 1999;27:1-12.
42. Sanwald-Ducray P, Dow J. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica. 1997;27:189-201.
43. Kawakami J, Yamamoto K, Sawada Y, Iga T. Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J Pharmacokinet Biopharm. 1994;22:207-227.
44. Tsunekawa Y, Hasegawa T, Nadai M, Takagi K, Nabeshima T. Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J Pharm Pharmacol. 1992;44:594-599.
45. Bregante MA, Saez P, Aramayona JJ, et al. Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows. Am J Vet Res. 1999;60:1111-1116.
46. Duthu GS. Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. J Pharm Sci. 1985;74:943-946.
47. Efthymiopoulos C, Battaglia R, Strolin Benedetti M. Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. J Antimicrob Chemother. 1991;27:517-526.
48. Jezequel SG. Fluconazole: Interspecies scaling and allometric relationships of pharmacokinetic properties. J Pharm Pharmacol. 1994;46:196-199.
49. Segre G, Bianchi E, Zanolo G. Pharmacokinetics of flunoxaprofen in rats, dogs, and monkeys. J Pharm Sci. 1988;77:670-673.
50. Khor SP, Amyx H, Davis ST, Nelson D, Baccanari DP, Spector T. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: Allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. Cancer Chemother Pharmacol. 1997;39:233-238.
51. Clark B, Smith DA. Metabolism and excretion of a chromone carboxylic acid (FPL 52757) in various animal species. Xenobiotica. 1982;12:147-153.
52. Nakajima Y, Hattori K, Shinsei M, et al. Physiologically-based pharmacokinetic analysis of grepafloxacin. Biol Pharm Bull. 2000;23:1077-1083.
53. Baggot JD. Application of interspecies scaling to the bispyridinium oxime HI-6. Am J Vet Res. 1994;55:689-691.
54. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, et al. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci. 1995;84:1285-1290.
55. Sakai T, Hamada T, Awata N, Watanabe J. Pharmacokinetics of an antiallergic agent, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H-benzimidazole difumarate (KG-2413) after oral administration: Interspecies differences in rats, guinea pigs and dogs. J Pharmacobio-Dyn. 1989;12:530-536.
56. Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffman AH, Chou RC. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol. 1996;48:573-577.
57. Richter WF, Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos. 1999;27:21-25.
58. Lapka R, Rejholec V, Sechser T, Peterkova M, Smid M. Interspecies pharmacokinetic scaling of metazosin, a novel alpha-adrenergic antagonist. Biopharm Drug Dispo. 1989;10:581-589.
59. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W. Pharmacokinetics of miglitol: Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneim Forsch. 1997;47:734-745.
60. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparison in humans and other mammalian species. J Antimicrob Chemother. 1999;43 (Suppl. B):69-76.
61. Lave T, Portmann R, Schenker G, et al. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol. 1999;51:85-91.
62. Higuchi S, Shiobara Y. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica. 1980;10:447-454.
63. Mitsuhashi Y, Sugiyama Y, Ozawa S, et al. Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up. Cancer Chemother Pharmacol. 1990;27:20-26.
64. Yoshimura M, Kojima J, Ito T, Suzuki J. Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. I. Studies on interspecies variation in laboratory animals. J Pharmacobio-Dyn. 1985;8:738-750.
65. Gombar CT, Harrington GW, Pylypiw HM Jr, et al. Interspecies scaling of the pharmacokinetics of N-nitrosodimethylamine. Cancer Res. 1990;50:4366-4370.
66. Mukai H, Watanabe S, Tsuchida K, Morino A. Pharmacokinetics of NS-49, a phenethylamine class a1A-adrenoceptor agonist, at therapeutic doses in several animal species and interspecies scaling of its pharmacokinetic parameters. Int J Pharm. 1999;186:215-222.
67. Owens SM, Hardwick WC, Blackall D. Phencyclidine pharmacokinetic scaling among species. J Pharmacol Exp Ther. 1987;242:96-101.
68. Ishigami M, Saburomaru K, Niino K, et al. Pharmacokinetics of procaterol in the rat, rabbit, and beagle dog. Arzneim Forsch. 1979;29:266-270.
69. Khor SP, McCarthy K, DuPont M, Murray K, Timony G. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. J Pharmacol Exp Ther. 2000;293:618-624.
70. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol. 1996;136:75-78.
71. Coassolo P, Fischli W, Clozel J-P, Chou RC. Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog, and primates. Xenobiotica. 1996;26:333-345.
72. Widman M, Nilsson LB, Bryske B, Lundstrom J. Disposition of remoxipride in different species. Arzneim Forsch. 1993;43:287-297.
73. Lashev L, Pashov D, Kanelov I. Species specific pharmacokinetics of rolitetracycline. J Vet Med A. 1995;42:201-208.
74. Herault JP, Donat F, Barzu T, et al. Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. Blood Coagul Fibrinol. 1997;8:161-167.
75. Ward KW, Azzarano LM, Bondinell WE, et al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos. 1999;27:1232-1241.
76. Lin C, Gupta S, Loebenberg D, Cayen MN. Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration. Antimicrob Ag Chemother. 2000;44:916-919.
77. Chung M, Radwanski E, Loebenberg D, et al. Interspecies pharmacokinetic scaling of Sch 34343. J Antimicrob Chemother. 1985;15 (Suppl. C):227-233.
78. Hinderling PH, Dilea C, Koziol T, Millington G. Comparative kinetics of sematilide in four species. Drug Metab Dispo. 1993;21:662-669.
79. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog, and man. Xenobiotica. 1999;29:297-310.
80. Brocks DR, Freed MI, Martin DE, et al. Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Pharm Res. 1996;13:794-797.
81. Cosson VF, Fuseau E, Efthymiopoulos C, Bye A. Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. J Pharmacokin Biopharm. 1997;25:149-167.
82. Leusch A, Troger W, Greischel A, Roth W. Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit, and monkey, and extrapolation to man. Xenobiotica. 2000;30:797-813.
83. van Hoogdalem EJ, Soeishi Y, Matsushima H, Higuchi S. Disposition of the selective a1A-adrenoceptor antagonist tamsulosin in humans: Comparison with data from interspecies scaling. J Pharm Sci. 1997;86:1156-1161.
84. Cruze CA, Kelm GR, Meredith MP. Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm Res. 1995;12:895-901.
85. Gaspari F, Bonati M. Interspecies metabolism and pharmacokinetic scaling of theophylline disposition. Drug Metab Rev. 1990;22:179-207.
86. Davi H, Tronquet C, Calx J, et al. Disposition of tiludronate (Skelid) in animals. Xenobiotica. 1999;29:1017-1031.
87. Pahlman I, Kankaanranta S, Palmer L. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Arzneim Forsch. 2001;51:134-144.
88. Tanaka E, Ishikawa A, Horie T. In vivo and in vitro trimethadione oxidation activity of the liver from various animal species including mouse, hamster, rat, rabbit, dog, monkey and human. Human Exp Toxicol. 1999;18:12-16.
89. Izumi T, Enomoto S, Hosiyama K, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther. 1996;277:1630-1641.
90. Grindel JM, O'Neil PG, Yorgey KA, et al. The metabolism of zomepirac sodium I. Disposition in laboratory animals and man. Drug Metab Dispo. 1980;8:343-348.
91. Singer MA, Morton AR. Mouse to elephant: Biological scaling and Kt/V. Am J Kidney Dis. 2000;35:306-309.
92. Singer MA. Of mice and men and elephants: Metabolic rate sets glomerular filtration rate. Am J Kidney Dis. 2001;37:164-178.
93. Edwards NA. Scaling of renal functions in mammals. Comp Biochem Physiol. 1975;52A:63-66.
94. Hayton WL. Maturation and growth of renal function: Dosing renally cleared drugs in children. AAPS PharmSci. 2000;2(1), article 3. Available from: http://www.pharmsci.org/scientificjournals/pharmsci/journal/3.html
95. Adolph EF. Quantitative relations in the physiological constituents of mammals. Science. 1949;109:579-585.
96. Rubner M. Über den enifluss der körpergrösse auf stoff und kraftwechsel. Z Biol. 1883;19:535-562.
97. Heusner A. Energy metabolism and body size. II. Dimensional analysis and energetic non-similarity. Resp Physiol. 1982;48:13-25.
98. West GB. The origin of universal scaling laws in biology. Physica A. 1999;263:104-113.
99. Murray CD. The physiological principle of minimum work. I. The vascular system and the cost of blood volume. Proc Natl Acad Sci U S A. 1926;12:207-214.
100. Cohn DL. Optimal systems: I. The vascular system. Bull Math Biophys. 1954;16:59-74.
101. Cohn DL. Optimal systems: II. The vascular system. Bull Math Biophys. 1955;17:219-227.
102. Bonate PL, Howard D. Prospective allometic scaling: Does the emperor have clothes? J Clin Pharmacol. 2000;40:665-670.
103. Mahmood I. Critique of prospective allometric scaling: Does the emperor have clothes? J Clin Pharmacol. 2000;40:671-674.